Noxopharm Limited announced the following senior appointments: Mr. Bhavin Raval has been appointed as Noxopharm Group Chief Financial Officer and Company Secretary (Nyrada); Dr. John Wilkinson has been appointed Noxopharm Chief Scientific Officer; Mr. James Bonnar has been appointed Vice-President, R&D (Nyrada); and Mr. Mark Waring has been appointed Senior Vice-President, US Operations (Nyrada).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.072 AUD | -7.69% | +14.29% | +1.41% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
1st Jan change | Capi. | |
---|---|---|
+1.41% | 14.06M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- NOX Stock
- News Noxopharm Limited
- Noxopharm Limited Announces Management Appointments